This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.
Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides
by Zacks Equity Research
The UroLift System remains a major contributor to Teleflex (TFX) revenues.
TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic
by Zacks Equity Research
On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.
Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View
by Zacks Equity Research
The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1
Teleflex (TFX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 17.62% and 2.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Teleflex (TFX) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.
Teleflex (TFX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 7.26% and 3.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.
Teleflex (TFX) Completes Buyout of Hemostatic Goods Producer
by Zacks Equity Research
Teleflex (TFX) to leverage its strength in enhancing clinical efficacy and patient safety via the recent buyout.
Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows
by Zacks Equity Research
Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.
Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.
Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 22.03% and 1.27%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 29 Earnings Roster: SYK, BAX & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Earnings Preview: Teleflex (TFX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
How Has TFX Performed 30 Days Post Earnings
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle
by Zacks Equity Research
The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.
Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract
by Zacks Equity Research
Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.
Teleflex (TFX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 55.65% and 6.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
Medical Products Stock Earnings on Jul 30: BAX, SYK & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.